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Introduction
The complex biochemistry of human biological systems has
been operationally broken down into a set of large molecular
categories1. The metabolome, as it is termed, includes four
classes of biologically active molecules including lipids1. Lipids
are an integral structural component of cell membranes, play a
significant role in energy storage, are involved in a variety of
signaling pathways and intersect with other classes of
compounds in the metabolome1. The lipidome has the ability to
influence membrane mediated events2. Distinct lipid profiles
have been identified in normal and pathologic conditions, and in
response to specific therapeutic interventions. One such
intervention is renal transplantation, the treatment of choice for
End Stage Renal Disease (ESRD)4. In the United States, a
shortage of suitable organ donors, and resultant organs,
creates a marked supply and demand discrepancy leaving
many patients on the waiting list for prolonged periods of time4.
Current immunosuppression protocols result in a substantial
decrease in T-cell mediated rejection at the cost of long term
immunosuppression, with its resultant adverse effects including
opportunistic infections4, graft damage, and metabolic
complications5. Additionally, these protocols do not have a
significant effect on suppressing antibody mediated rejection
(AMR), a major cause of graft loss6. Management of
immunosuppression for individual patients is currently
generalized based on protocols. Presently available biomarkers
like donor-specific antibodies and degree of sensitization have
proven to be inadequate to predict rejection6. Thus, there is an
unmet need for biomarkers which could allow for better risk
stratification to enhance the benefit and limit the risk of the
immunosuppression therapy for individual patients.
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Figure 1: Significant differences are observed among
phospholipids at T1 between SC and AMR. A) AMR group showed a
significant lower concentration of PC, PE, and LPE. There was a trend
towards higher levels of LPC in AMR. B) The ratio of PLs degradation to
produce LPLs is an indication of PLA2 activity with lower values
suggesting higher activity. AMR group presented lower ratio for both
more PC/LPC and PE/LPE. Suspected outliers are indicated by open
circles in the box plot. Green rectangles represent AMR and the Red
rectangles represent SC. * indicates significant differences with p<0.05.

Figure 4: Lipids predict potential for AMR on the day of
transplant. A) Box plot of normalized concentration shows that
AMR group has lower concentration of the lipids predictors.
Suspected outliers are represented as open circles that appear
outside the whiskers. The validation method showed that the
predict model can discriminate SC and AMR in the day of
transplant with 0.022 OOB error. The mean Decrease Accuracy
method shows that DSA is the more important predictor, followed
by LPE (16:0) and PC (18:0/20:4) and they independently could be
used as biomarkers. The analysis also reveals that when
considering these predictors as biomarkers, the inclusion of LPE
(20:4) and LPE (22:6) does not add any predictive power, and
rather must be use to compose the RLDA model. * indicates
significant differences with p<0.01.
Figure 5: Specific lipids characterize the difference between T1
and T2 among SC patients.

Conclusions and Future Directions
Our study for the first time, identify the lipid differences pretransplant and post-transplant. Additionally, we identify a pre
transplant lipid signature that distinguish kidney transplant patients
with favorable transplant outcomes (SC) and a major form of nonfavorable transplant outcomes (AMR). We further demonstrate that
unlike SC patients that demonstrate a dynamic longitudinal lipid
change, AMR patients maintain a relatively unchanging lipid profile
over time with respect to the measured lipids. Finally, we
demonstrate for the first time the potential for risk stratification of
kidney transplant patients on the day of transplant with respect to
the potential for onset of AMR. Following validation in a larger
cohort, these findings have the potential to alter the current
paradigm of post-transplant monitoring and treatment of these
patients via an evidence based risk stratification strategy and
thereby vastly improving the success of kidney transplantation.
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The study population consisted of 16 consecutive patients
who developed antibody-mediated rejection within 2 years of
kidney transplant and 29 stable control (SC) patients who did not
develop rejection at any point of post- transplant follow-up. Serial
plasma samples are collected and stored at Time 1 (T1 - pretransplant), Month 6 (T2) and Month 12(T3) and then yearly for
all patient’s post-transplant as part of an IRB approved biobank
protocol at our institution. Indication biopsies were performed for
acute allograft dysfunction defined as a rise in creatinine >20%
above baseline, serum creatinine nadir ≥2.0 mg/dL posttransplant; or delayed graft function >21 days post-transplant.
Surveillance biopsies were performed in patients with a positive
flow-cytometric crossmatch (T or B >100 mean channel shifts)
and/or presence of pre- formed donor-specific antibody [DSA;
>5000 mean fluorescent intensity (MFI)] at 1 month and 6-month
post-transplant. Biopsies were graded based upon the Banff
criteria12. Patients with AMR were treated with 6-9 sessions of
plasmapheresis with intravenous immunoglobulin (IVIG). Pretransplant complement-dependent cytotoxicity (CDC) assays
and three-color flow- cytometric cross matching (FCXM) were
performed for all patients at the time of transplant. Donorspecific antibodies (DSA) were analyzed using the Luminex
platform.
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Figure 2: The RLDA model generated using 4 lipids and DSA
demonstrate good separation between AMR and SC groups. The
RLDA plot shows the clear separation of the patients in the two groups
based on the Mahalanobis distance. This method determines whether
the selected predictors can separate the distinct categories and reveals
the presence of outliers in in the AMR and SC groups. Blue dot among
the red dots indicates the one misclassified patient based in the
predictive model. Internal ellipse indicates the 95% confidence region to
contain the true mean of the group. External ellipse indicates the region
estimated to contain 50% of group’ population.
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